Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 6/20 | 0.55 |
| ▸ | METAP2 | P50579 | 2/20 | 0.55 |
| ▸ | METAP1 | P53582 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9052059 | 0.98 | RAB9A (0.66) | RAB9AMAPTKDM4ELMNAMETAP2 | |
| SCHEMBL4386263 | 0.86 | KDM4E (0.72) | RAB9AMAPTKDM4ELMNAMETAP2 | |
| SCHEMBL9447019 | 0.84 | KDM4E (0.57) | RAB9AMAPTKDM4ELMNAHTT | |
| SCHEMBL8203474 | 0.84 | KDM4E (0.57) | RAB9AMAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL6222129 | 0.84 | KDM4E (0.57) | RAB9AMAPTKDM4ELMNAHTT | |
| SCHEMBL8043868 | 0.82 | LMNA (0.57) | RAB9AMAPTKDM4ELMNAMETAP2 | |
| SCHEMBL7208902 | 0.82 | KDM4E (0.54) | RAB9AMAPTKDM4ELMNAHTT | |
| SCHEMBL7212405 | 0.82 | KDM4E (0.54) | RAB9AMAPTKDM4ELMNAHTT | |
| SCHEMBL9446981 | 0.82 | KDM4E (0.54) | RAB9AMAPTKDM4ELMNAHTT | |
| SCHEMBL6026678 | 0.81 | RAB9A (0.69) | RAB9AMAPTKDM4ELMNAMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153791-B2 | substituted pyrimidine compoundssuch as 4-amino-6-(3-chloro-4-fluoro-phenylamino)-pyrimidine-5-carbaldehyde O-methyl oxime, used for treating, preventing or ameliorating a chronic or acute protein kinase mediated diseasea, disorders or conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-10 | — | — | US | claimed |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | US | claimed |
| EP-1075483-B1 | HYGROMYCIN A DERIVATIVES | PFIZER PROD INC (US) | 2003-12-03 | — | — | EP | claimed |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | STEWART ANDREW O (US) | 2003-11-27 | — | — | US | claimed |
| EP-1077984-B1 | 2\"-DEOXY HYGROMYCIN DERIVATIVES | PFIZER PROD INC (US) | 2003-06-18 | — | — | EP | claimed |
| US-6342497-B1 | 2″-deoxy hygromycin derivatives | PFIZER INC | 2002-01-29 | — | — | US | claimed |
| US-6313100-B1 | ANTIBACTERIAL, ANTIPROTOZOA AGENTS | PFIZER INC | 2001-11-06 | — | — | US | claimed |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | claimed |
| EP-0445731-B1 | Azabicyclo and azacyclo oxime and amine cholinergic agents and pharmaceutically acceptable salts thereof | WARNER LAMBERT CO (US) | 1996-01-10 | — | — | EP | claimed |
| US-5482938-A | Azabicyclo and azacyclo oxime and amine cholinergic agents and methods of treatment | WARNER-LAMBERT COMPANY (US) | 1996-01-09 | — | — | US | claimed |
| EP-4392397-A2 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | AbbVie Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-118043320-A | Polymorphs having pesticidal activity | 科迪华农业科技有限责任公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2023028558-A2 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | ABBVIE INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20230002389-A1 | ADENINE ANALOGS, PRODRUGS, DERIVATIVES, COMPOSITIONS AND USES THEREOF | PADIA JANAK KHIMCHAND (US) | 2023-01-05 | — | — | US | disclosed |
| EP-3380469-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-4728668-A | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments | USV PHARMACEUTICAL CORPORATION (US) | 1988-03-01 | — | — | US | disclosed |
| US-4725619-A | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments | USV PHARMACEUTICAL CORPORATION (US) | 1988-02-16 | — | — | US | disclosed |
| US-4631287-A | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments | USV PHARMACEUTICAL CORP. (US) | 1986-12-23 | — | — | US | disclosed |
| EP-0200101-A2 | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive aliments | USV PHARMACEUTICAL CORPORATION (US) | 1986-11-05 | — | — | EP | disclosed |
| EP-0154142-A1 | Substituted hexahydro arylquinolizines | MERCK & CO. INC. (US) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | RAB9A 1542/4885MAPT 3906/4885KDM4E 4588/4885 |
| US-20230002389-A1 | ADENINE ANALOGS, PRODRUGS, DERIVATIVES, COMPOSITIONS AND USES THEREOF | APRT, HPRT1, NUDT1 | RAB9A 1168/4885MAPT 2688/4885KDM4E 1821/4885 |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | RAB9A 1542/4885MAPT 3906/4885KDM4E 4588/4885 |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | MAP3K2, MAP3K1, MAP3K20 | RAB9A 3964/4885MAPT 3084/4885KDM4E 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.